Significantly more patients receiving cytisinicline versus placebo had continuous e-cigarette abstinence at the end of treatment
Benefit seen with additional six weeks of treatment after six weeks of initial failure with varenicline or nicotine replacement
Vaping tied to greater cigarette quitting in more recent years
However, ongoing use of e-cigarettes with nicotine was high
Quit rate higher for ECs than nicotine replacement therapy; at six months, 62.8 percent in EC arm still using ECs
Based on moderate-quality evidence, direct association seen for greater intensity of behavioral therapy with efficacy findings
Dulaglutide effective in preventing substantial weight gain, which was more common in women
Combination of a patch and fast-acting nicotine replacement therapy also effective
Cytisinicline well tolerated with only 2.9 percent of participants discontinuing due to an adverse event
Reduced risk seen for all CVD events, respiratory system disease events, hospitalization due to CVD or RSD, adverse birth outcomes